دورية أكاديمية
أعرض في EDS

Metformin beyond type 2 diabetes: Emerging and potential new indications.

التفاصيل البيبلوغرافية
العنوان: Metformin beyond type 2 diabetes: Emerging and potential new indications.
المؤلفون: Petrie JR; School of Health and Wellbeing, University of Glasgow, Glasgow, UK.
المصدر: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2024 Aug; Vol. 26 Suppl 3, pp. 31-41. Date of Electronic Publication: 2024 Jul 04.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 100883645 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1463-1326 (Electronic) Linking ISSN: 14628902 NLM ISO Abbreviation: Diabetes Obes Metab Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Oxford : Wiley-Blackwell, c1999-
مواضيع طبية MeSH: Metformin*/therapeutic use , Hypoglycemic Agents*/therapeutic use , Polycystic Ovary Syndrome*/drug therapy , Polycystic Ovary Syndrome*/complications , Prediabetic State*/drug therapy , Diabetes, Gestational*/drug therapy , Diabetes Mellitus, Type 2*/drug therapy , Diabetes Mellitus, Type 2*/complications, Humans ; Pregnancy ; Female ; Diabetes Mellitus, Type 1/drug therapy ; Diabetes Mellitus, Type 1/complications ; Neoplasms/prevention & control ; Neoplasms/drug therapy ; Alzheimer Disease/drug therapy ; Alzheimer Disease/prevention & control ; Off-Label Use ; Pregnancy in Diabetics/drug therapy
مستخلص: Metformin is best known as a foundational therapy for type 2 diabetes but is also used in other contexts in clinical medicine with a number of emerging and potential indications. Many of its beneficial effects may be mediated by modest effects on weight loss and insulin sensitivity, but it has multiple other known mechanisms of action. Current clinical uses beyond type 2 diabetes include: polycystic ovarian syndrome; diabetes in pregnancy/gestational diabetes; prevention of type 2 diabetes in prediabetes; and adjunct therapy in type 1 diabetes. As metformin has been in clinical use for almost 70 years, much of the underpinning evidence for its use in these conditions is, by definition, based on trials conducted before the advent of contemporary evidence-based medicine. As a result, some of the above-established uses are 'off-label' in many regulatory territories and their use varies accordingly in different countries. Going forward, several current 'repurposing' investigational uses of metformin are also being investigated: prevention of cancer (including in Li Fraumeni syndrome), renal protection, Alzheimer's disease, metabolic dysfunction-associated steatotic liver disease and promotion of healthy ageing. Despite the longevity of metformin and its important current roles beyond type 2 diabetes in clinical medicine, it has further potential and much research is ongoing.
(© 2024 The Author(s). Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.)
References: Davies MJ, Aroda VR, Collins BS, et al. Management of Hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45(11):2753‐2786.
Marx N, Federici M, Schütt K, et al. 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023;44(39):4043‐4140.
Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin. Diabetologia. 2017;60(9):1577‐1585.
Steinberg GR, Hardie DG. New insights into activation and function of the AMPK. Nat Rev Mol Cell Biol. 2023;24(4):255‐272.
McCreight LJ, Bailey CJ, Pearson ER. Metformin and the gastrointestinal tract. Diabetologia. 2016;59(3):426‐435.
Day EA, Ford RJ, Smith BK, et al. Metformin‐induced increases in GDF15 are important for suppressing appetite and promoting weight loss. Nat Metab. 2019;1(12):1202‐1208.
Jenkins AJ, Welsh P, Petrie JR. Metformin, lipids and atherosclerosis prevention. Curr Opin Lipidol. 2018;29(4):346‐353.
Kristófi R, Eriksson JW. Metformin as an anti‐inflammatory agent: a short review. J Endocrinol. 2021;251(2):R11‐R22.
Metformin 500 mg film coated Tablets—Summary of Product Characteristics (SmPC)—(emc) (medicines.org.uk). https://www.medicines.org.uk/emc/product/10759/smpc Accessed 4 April 2024.
Glucophage SR 500 mg prolonged release tablets—Summary of Product Characteristics (SmPC)—(emc) (medicines.org.uk).
Teede HJ, Tay CT, Laven J, et al. Recommendations from the 2023 international evidence‐based guideline for the assessment and management of polycystic ovary syndrome. Fertil Steril. 2023;120(4):767‐793.
Zhang J, Xu JH, Qu QQ, Zhong GQ. Risk of cardiovascular and cerebrovascular events in polycystic ovarian syndrome women: a meta‐analysis of cohort studies. Front Cardiovasc Med. 2020;7:552421.
Harborne L, Fleming R, Lyall H, Norman J, Sattar N. Descriptive review of the evidence for the use of metformin in polycystic ovary syndrome. Lancet. 2003;361(9372):1894‐1901.
Bader S, Bhatti R, Mussa B, Abusanana S. A systematic review of GLP‐1 on anthropometrics, metabolic and endocrine parameters in patients with PCOS. Womens Health (Lond). 2024;20:17455057241234530. doi:10.1177/17455057241234530.
Goldberg A, Graca S, Liu J, et al. Anti‐obesity pharmacological agents for polycystic ovary syndrome: a systematic review and meta‐analysis to inform the 2023 international evidence‐based guideline. Obes Rev. 2024;25:e13704. doi:10.1111/obr.13704.
Melin J, Forslund M, Alesi S, et al. Metformin and combined oral contraceptive pills in the management of polycystic ovary syndrome: a systematic review and meta‐analysis. J Clin Endocrinol Metab. 2024;109(2):e817‐e836.
Melin JM, Forslund M, Alesi SJ, et al. Effects of different insulin sensitisers in the management of polycystic ovary syndrome: a systematic review and meta‐analysis. Clin Endocrinol (Oxf). 2024;100(2):149‐163.
Vogel B, Acevedo M, Appelman Y, et al. The lancet women and cardiovascular disease commission: reducing the global burden by 2030. Lancet. 2021;397(10292):2385‐2438.
Lindsay RS, Loeken MR. Metformin use in pregnancy: promises and uncertainties. Diabetologia. 2017;60(9):1612‐1619.
Rowan JA, Hague WM, Gao W, Battin MR, Moore MP, MiG Trial Investigators. Metformin versus insulin for the treatment of gestational diabetes. N Engl J Med. 2008;358(19):2003‐2015.
Dunne F, Newman C, Alvarez‐Iglesias A, et al. Early metformin in gestational diabetes: a randomized clinical trial. JAMA. 2023;330(16):1547‐1556.
Cassina M, Donà M, Di Gianantonio E, Litta P, Clementi M. First‐trimester exposure to metformin and risk of birth defects: a systematic review and meta‐analysis. Hum Reprod Update. 2014;20(5):656‐669.
Abolhassani N, Winterfeld U, Kaplan YC, et al. Major malformations risk following early pregnancy exposure to metformin: a systematic review and meta‐analysis. BMJ Open Diabetes Res Care. 2023;11(1):e002919.
Gordon HG, Atkinson JA, Tong S, et al. Metformin in pregnancy and childhood neurodevelopmental outcomes: a systematic review and meta‐analysis. Am J Obstet Gynecol. 2024;S0002‐9378(24)00430–7. doi:10.1016/j.ajog.2024.02.316 Epub ahead of print.
Hanem LGE, Salvesen Ø, Juliusson PB, et al. Intrauterine metformin exposure and offspring cardiometabolic risk factors (PedMet study): a 5–10 year follow‐up of the PregMet randomised controlled trial. Lancet Child Adolesc Health. 2019;3(3):166‐174.
Paavilainen E, Tertti K, Nikkinen H, et al. Metformin versus insulin therapy for gestational diabetes: effects on offspring anthropometrics and metabolism at the age of 9 years: a follow‐up study of two open‐label, randomized controlled trials. Diabetes Obes Metab. 2022;24(3):402‐410.
Chiswick CA, Reynolds RM, Denison FC, et al. Does Metformin Reduce Excess Birthweight in Offspring of Obese Pregnant Women? A Randomised Controlled Trial of Efficacy, Exploration of Mechanisms and Evaluation of Other Pregnancy Complications. NIHR Journals Library; 2016.
American Diabetes Association Professional Practice Committee. 15. Management of diabetes in pregnancy: standards of care in diabetes—2024. Diabetes Care. 2024;47(Supplement_1):S282‐S294.
Feig DS, Donovan LE, Zinman B, et al. Metformin in women with type 2 diabetes in pregnancy (MiTy): a multicentre, international, randomised, placebo‐controlled trial. Lancet Diabetes Endocrinol. 2020;8(10):834‐844. Erratum in: Lancet Diabetes Endocrinol. 2020;8(11):e6.
American Diabetes Association. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes—2021. Diabetes Care. 2021;44(Supplement_1):S15‐S33.
Knowler WC, Barrett‐Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393‐403.
Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the diabetes prevention program outcomes study. Lancet Diabetes Endocrinol. 2015;3(11):866‐875.
Hostalek U, Campbell I. Metformin for diabetes prevention: update of the evidence base. Curr Med Res Opin. 2021;37(10):1705‐1717.
Patel D, Ayesha IE, Monson NR, et al. The effectiveness of metformin in diabetes prevention: a systematic review and meta‐analysis. Cureus. 2023;15(9):e46108.
Herman WH, Ratner RE. Metformin should be used to treat prediabetes in selected individuals. Diabetes Care. 2020;43(9):1988‐1990.
Davidson MB. Metformin should not be used to treat prediabetes. Diabetes Care. 2020;43(9):1983‐1987.
American Diabetes Association Professional Practice Committee. Prevention or delay of diabetes and associated comorbidities: standards of Care in Diabetes—2024. Diabetes Care. 2024;47(Suppl. 1):S43‐S51.
Petrie JR, Rossing PR, Campbell IW. Metformin and cardiorenal outcomes in diabetes: a reappraisal. Diabetes Obes Metab. 2020;22(6):904‐915.
Griffin SJ, Bethel MA, Holman RR, et al. Metformin in non‐diabetic hyperglycaemia: the GLINT feasibility RCT. Health Technol Assess. 2018;22(18):1‐64.
https://www.clinicaltrials.gov/study/NCT02915198. Accessed 4 April 2024.
Van der Schueren B, Ellis D, Faradji RN, Al‐Ozairi E, Rosen J, Mathieu C. Obesity in people living with type 1 diabetes. Lancet Diabetes Endocrinol. 2021;9(11):776‐785.
Cleland SJ, Fisher BM, Colhoun HM, Sattar N, Petrie JR. Insulin resistance in type 1 diabetes: what is ‘double diabetes’ and what are the risks? Diabetologia. 2013;56(7):1462‐1470.
Conway B, Miller RG, Costacou T, et al. Temporal patterns in overweight and obesity in type 1 diabetes. Diabet Med. 2010;27:398‐404.
https://www.diabetesinscotland.org.uk/wp‐content/uploads/2023/10/Scottish‐Diabetes‐Survey‐2022.pdf. Accessed 4 April 2024.
Liu LL, Lawrence JM, Davis C, et al. Prevalence of overweight and obesity in youth with diabetes in USA: the SEARCH for diabetes in youth study. Pediatr Diabetes. 2010;11:4‐11.
Livingstone R, Boyle JG, Petrie JR, REMOVAL Study Team. A new perspective on metformin therapy in type 1 diabetes. Diabetologia. 2017;60(9):1594‐1600.
Vella S, Buetow L, Royle P, Livingstone S, Colhoun HM, Petrie JR. The use of metformin in type 1 diabetes: a systematic review of efficacy. Diabetologia. 2010;53(5):809‐820.
https://www.nice.org.uk/guidance/ng17/chapter/Recommendations#blood‐glucose‐management. Accessed 4 April 2024.
American Diabetes Association. Standards of medical care in diabetes. Diabetes Care. 2017;40(Suppl 1):S1‐S135.
Libman IM, Miller KM, DiMeglio LA, et al. Effect of metformin added to insulin on glycemic control among overweight/obese adolescents with type 1 diabetes: a randomized clinical trial. JAMA. 2015;314(21):2241‐2250.
Petrie JR, Chaturvedi N, Ford I, et al. Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double‐blind, randomised, placebo‐controlled trial. Lancet Diabetes Endocrinol. 2017;5(8):597‐609.
Willeit P, Tschiderer L, Allara E, et al. Carotid intima‐media thickness progression as surrogate marker for cardiovascular risk: meta‐analysis of 119 clinical trials involving 100 667 patients. Circulation. 2020;142(7):621‐642.
Timmons JG, Greenlaw N, Boyle JG, et al. Metformin and carotid intima‐media thickness in never‐smokers with type 1 diabetes: the REMOVAL trial. Diabetes Obes Metab. 2021;23(6):1371‐1378.
Meng H, Zhang A, Liang Y, Hao J, Zhang X, Lu J. Effect of metformin on glycaemic control in patients with type 1 diabetes: a meta‐analysis of randomized controlled trials. Diabetes Metab Res Rev. 2018;34:e2983.
American Diabetes Association professional practice committee. 9. Pharmacologic approaches to glycemic treatment: standards of Care in Diabetes‐2024. Diabetes Care. 2024;47(Suppl 1):S158‐S178.
Mesquita LA, Spiazzi BF, Piccoli GF, et al. Does metformin reduce the risk of cancer in obesity and diabetes? A systematic review and meta‐analysis. Diabetes Obes Metab. 2024;26:1929‐1940. doi:10.1111/dom.15509.
Thakkar B, Aronis KN, Vamvini MT, Shields K, Mantzoros CS. Metformin and sulfonylureas in relation to cancer risk in type II diabetes patients: a meta‐analysis using primary data of published studies. Metabolism. 2013;62(7):922‐934.
Wu L, Zhu J, Prokop LJ, Murad MH. Pharmacologic therapy of diabetes and overall cancer risk and mortality: a meta‐analysis of 265 studies. Sci Rep. 2015;15(5):10147.
Papadakos SP, Ferraro D, Carbone G, et al. The emerging role of metformin in the treatment of hepatocellular carcinoma: is there any value in repurposing metformin for HCC immunotherapy? Cancers (Basel). 2023;15(12):3161.
https://www.fundingawards.nihr.ac.uk/award/NIHR131239. Accessed 4 April 2024.
ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560‐2572.
Corremans R, Neven E, Maudsley S, et al. Progression of established non‐diabetic chronic kidney disease is halted by metformin treatment in rats. Kidney Int. 2022;101(5):929‐944.
Roumie CL, Chipman J, Min JY, et al. Association of treatment with metformin vs sulfonylurea with major adverse cardiovascular events among patients with diabetes and reduced kidney function. JAMA. 2019;322(12):1167‐1177.
Charytan DM, Solomon SD, Ivanovich P, et al. Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab. 2019;21:1199‐1208.
Hu Y, Lei M, Ke G, et al. Metformin use and risk of all‐cause mortality and cardiovascular events in patients with chronic kidney disease‐a systematic review and meta‐analysis. Front Endocrinol (Lausanne). 2020;11:559446.
https://clinicaltrials.gov/study/NCT03831464. Accessed 4 April 2024.
Satriano J, Sharma K, Blantz RC, Deng A. Induction of AMPK activity corrects early pathophysiological alterations in the subtotal nephrectomy model of chronic kidney disease. Am J Physiol Renal Physiol. 2013;305(5):F727‐F733.
Bell S, Farran B, McGurnaghan S, et al. Risk of acute kidney injury and survival in patients treated with metformin: an observational cohort study. BMC Nephrol. 2017;18(1):163.
Adem MA, Decourt B, Sabbagh MN. Pharmacological approaches using diabetic drugs repurposed for Alzheimer's disease. Biomedicines. 2024;12(1):99.
Chen Y, Zhao S, Fan Z, et al. Metformin attenuates plaque‐associated tau pathology and reduces amyloid‐β burden in APP/PS1 mice. Alzheimers Res Ther. 2021;13(1):40.
Zheng J, Xu M, Walker V, et al. Evaluating the efficacy and mechanism of metformin targets on reducing Alzheimer's disease risk in the general population: a Mendelian randomisation study. Diabetologia. 2022;65:1664‐1675.
Luo A, Ning P, Lu H, et al. Association between metformin and Alzheimer's disease: a systematic review and meta‐analysis of clinical observational studies. J. Alzheimer's Dis. 2022;88:1311‐1323.
https://clinicaltrials.gov/study/NCT04098666. Accessed 4 April 2024.
https://clinicaltrials.gov/study/NCT05109169. Accessed 4 April 2024.
https://clinicaltrials.gov/study/NCT04511416. Accessed 4 April 2024.
Hegazi OE, Alalalmeh SO, Shahwan M, et al. Exploring promising therapies for non‐alcoholic fatty liver disease: a ClinicalTrials.gov analysis. Diabetes Metab Syndr Obes. 2024;17:545‐561.
Blazina I, Selph S. Diabetes drugs for nonalcoholic fatty liver disease: a systematic review. Syst Rev. 2019;8(1):295.
Martin‐Montalvo A, Mercken EM, Mitchell SJ, et al. Metformin improves healthspan and lifespan in mice. Nat Commun. 2013;4:2192.
https://clinicaltrials.gov/study/NCT02432287. Accessed 4 April 2024.
Parish AJ, Swindell WR. Metformin has heterogeneous effects on model organism lifespans and is beneficial when started at an early age in Caenorhabditis elegans: a systematic review and meta‐analysis. Aging Cell. 2022;21(12):e13733.
Mohammed I, Hollenberg MD, Ding H, Triggle CR. A critical review of the evidence that metformin is a putative anti‐aging drug that enhances Healthspan and extends lifespan. Front Endocrinol (Lausanne). 2021;12:718942.
Konopka AR, Miller BF. Taming expectations of metformin as a treatment to extend healthspan. Geroscience. 2019;41(2):101‐108.
فهرسة مساهمة: Keywords: antidiabetic drug; glycaemic control; metformin; type 1 diabetes; type 2 diabetes
المشرفين على المادة: 9100L32L2N (Metformin)
0 (Hypoglycemic Agents)
تواريخ الأحداث: Date Created: 20240705 Date Completed: 20240718 Latest Revision: 20240718
رمز التحديث: 20240718
DOI: 10.1111/dom.15756
PMID: 38965738
قاعدة البيانات: MEDLINE
الوصف
تدمد:1463-1326
DOI:10.1111/dom.15756